» COVID-19 Information


Manage your account, request prescriptions, set up appointments & more.

Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label



Clinical Trial Title

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Trial Status

Closed to Enrollment

Start Date

August 24, 2004

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Brain cancer - Medulloblastoma (Standard Risk)


This randomized phase III trial is studying how well standard-dose radiation therapy works compared to reduced-dose radiation therapy in children 3-7 years of age AND how well standard volume boost radiation therapy works compared to smaller volume boost radiation therapy when given together with chemotherapy in treating young patients who have undergone surgery for newly diagnosed standard-risk medulloblastoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as vincristine, cisplatin, lomustine, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy with chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether standard-dose radiation therapy is more effective than reduced-dose radiation therapy when given together with chemotherapy after surgery in treating young patients with medulloblastoma.

Eligibility Criteria

Age:  > 3 years and < 7 years at the time of diagnosis


  • The presence of a posterior fossa medulloblastoma as determined by institutional pathologic evaluation.  Pre-operative and post-operative cranial MRI with and without contract must be available.
  • Patients with anaplastic medulloblastoma will NOT be eligible
  • Patients with brain stem involvement are eligible
  • Presence of minimal volume, non-disseminated disease
  • No evidence of metastatic disease in the head, spine, or CSF

Organ Function Requirement:    Adequate kidney, liver, and bone marrow. 



Study status is:
Completed: The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program


(503) 276-9300

Last Updated: Wednesday, January 27, 2021 11:41:08 AM